Corvus Pharmaceuticals, Inc. CRVS

Set alert

Price alert · CRVS

All alert types
9.88 USD +0.18 +1.80%

As of Nov 3, 2:52 PM ET

Bid
9.87 × 2
Ask
9.88 × 2
9.73 Day range 10.06
6.39 52-week range 26.95
YTD
+28.25%
1 year
+28.58%
Open
9.73
Prev close
9.70
Mkt cap
830.69M
Vol
416.08K
Avg vol
1.00M
EPS
-0.62
P/E
0.00
Div yield
0.00%
More statistics
Low
9.73
High
10.06
Forward P/E
-11.75
Beta
0.86
Short ratio
25.31
Inst. own
85.73%
Dividend
0.00
Ex-div date
Earnings
Nov 3, 2026
50-d avg
13.94
200-d avg
14.03
1y target
33.14

5D chart

Chart tools
Interval

Signals (101)
NameTimeAgo
SMA: BearishNov 2, 3:55 PM22 hours ago
SMA: BullishNov 2, 3:40 PM23 hours ago
SMA: BullishNov 2, 3:40 PM23 hours ago
SMA: BearishNov 2, 3:35 PM23 hours ago
SMA: BearishNov 2, 3:35 PM23 hours ago
SMA: BullishNov 2, 2:50 PM1 day ago
MACD: Buy SignalNov 2, 2:50 PM1 day ago
MACD: Sell SignalNov 2, 2:20 PM1 day ago
MACD: Buy SignalNov 2, 2:15 PM1 day ago
SMA: BullishNov 2, 2:10 PM1 day ago
MACD: Sell SignalNov 2, 1:45 PM1 day ago
SMA: BearishNov 2, 1:30 PM1 day ago
SMA: BearishNov 2, 1:30 PM1 day ago
SMA: BullishNov 2, 12:55 PM1 day ago
SMA: BearishNov 2, 12:05 PM1 day ago
MACD: Buy SignalNov 2, 11:40 AM1 day ago
SMA: BullishNov 2, 11:30 AM1 day ago
RSI: OversoldNov 2, 10:55 AM1 day ago
SMA: BearishNov 2, 10:30 AM1 day ago
SMA: BullishNov 2, 10:20 AM1 day ago

Newest 20 of 101.

Analyst view

Price target (mean) 33.14 +235.6% upside
Target (low)
27.00
Target (mean)
33.14
Target (high)
42.00
Ratings (0m) 8 8 buy · 0 hold · 0 sell
  • Strong buy1
  • Buy7
  • Hold0
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 8
  • 1 month ago 8
  • 2 months ago 7

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

CRVS analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.205-0.22 – -0.18-0.12-70.8%00.0%4
Next quarter-0.2275-0.25 – -0.18-0.15-51.7%00.0%4
Current year-0.7775-0.81 – -0.71-0.5373-44.7%00.0%4
Next year-1.07-1.28 – -0.83-0.7775-37.3%4.55M0.0%4

Upgrades and downgrades

The latest rating changes

CRVS analyst upgrades and downgrades
DateFirmActionFromTo
Apr 17, 2026Goldman SachsInitiated—Buy
Mar 13, 2026OppenheimerReiteratedOutperformOutperform
Jan 22, 2026JefferiesMaintainedBuyBuy
Jan 21, 2026OppenheimerMaintainedOutperformOutperform
Jan 21, 2026BarclaysMaintainedOverweightOverweight
Jan 20, 2026HC Wainwright & Co.MaintainedBuyBuy
Oct 13, 2025BarclaysInitiated—Overweight
May 20, 2025MizuhoMaintainedOutperformOutperform
May 9, 2025OppenheimerReiteratedOutperformOutperform
Mar 26, 2025OppenheimerMaintainedOutperformOutperform
Mar 26, 2025HC Wainwright & Co.ReiteratedBuyBuy
Jan 14, 2025HC Wainwright & Co.ReiteratedBuyBuy
Jan 2, 2025HC Wainwright & Co.Initiated—Buy
Nov 13, 2024OppenheimerReiteratedOutperformOutperform
Sep 16, 2024Ladenburg ThalmannMaintainedBuyBuy
May 7, 2024OppenheimerMaintainedOutperformOutperform
Apr 1, 2024Cantor FitzgeraldReiterated—Overweight
Mar 27, 2024MizuhoMaintainedNeutralNeutral
Mar 20, 2024OppenheimerMaintainedOutperformOutperform
Sep 7, 2023Cantor FitzgeraldReiteratedOverweightOverweight
Jun 16, 2023MizuhoReiteratedNeutralNeutral
May 30, 2023Ladenburg ThalmannMaintainedBuyBuy
May 9, 2023Cantor FitzgeraldMaintained—Overweight
Mar 30, 2023MizuhoReiterated—Neutral
Oct 7, 2022Ladenburg ThalmannInitiated—Buy
Dec 3, 2021Cantor FitzgeraldMaintained—Overweight
Dec 1, 2021JefferiesInitiated—Buy
Aug 3, 2021MizuhoMaintained—Neutral
Jul 16, 2021HC Wainwright & Co.Maintained—Buy
May 27, 2021Cantor FitzgeraldInitiated—Overweight